Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges

Sander Lefere; Lindsey Devisscher; Frank Tacke

doi:10.1080/13543784.2020.1718106

Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges

Expert Opin Investig Drugs. 2020 Feb;29(2):89-92. doi: 10.1080/13543784.2020.1718106. Epub 2020 Jan 20.

Authors

Sander Lefere¹, Lindsey Devisscher², Frank Tacke³

Affiliations

¹ Department of Gastroenterology and Hepatology, Hepatology Research Unit, Ghent University, Ghent, Belgium.
² Department of Basic and Applied Medical Sciences, Gut-Liver Immunopharmacology Unit, Ghent University, Ghent, Belgium.
³ Department of Hepatology and Gastroenterology, Charité University Medical Center, Berlin, Germany.

PMID: 31952447
DOI: 10.1080/13543784.2020.1718106

No abstract available

Keywords: CCR2 inhibition; CCR5 inhibition; NAFLD; Nonalcoholic steatohepatitis; cenicriviroc; hepatocellular carcinoma; liver fibrosis; macrophage; pharmacotherapy.

Publication types

Editorial

MeSH terms

Animals
CCR5 Receptor Antagonists / pharmacology
Drug Development
Humans
Liver Cirrhosis / drug therapy*
Liver Cirrhosis / physiopathology
Non-alcoholic Fatty Liver Disease / drug therapy*
Non-alcoholic Fatty Liver Disease / physiopathology
Receptors, CCR2 / antagonists & inhibitors
Receptors, CCR2 / metabolism
Receptors, CCR5 / drug effects
Receptors, CCR5 / metabolism

Substances

CCR2 protein, human
CCR5 Receptor Antagonists
CCR5 protein, human
Receptors, CCR2
Receptors, CCR5